



May 15, 2022

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001
Scrip Code: 532531

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051
Scrip code: STAR

Dear Madam/ Sir,

Sub: Clarification on news item appeared online based on a report filed by Press Trust of India (PTI) titled “Unable to sell Sputnik Light stock, Stelis Biopharma requests PM Modi for procurement of jobs.”

We refer to the above story that appeared online on May 14, 2022, and wish to submit that Stelis Biopharma Limited (Stelis), an associate of Strides Pharma Science Limited (Strides), has submitted its clarification to the Press Trust of India (PTI).

A copy of the letter is attached for your reference.

We request you to take the above on record.

Thanks & Regards,

For **Strides Pharma Science Limited**,

Manjula Ramamurthy
Company Secretary



Encl. As above

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India | Tel: +91 80 6784 0000 Fax: +91 80 6784 0700

Regd Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India | Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942

corpcomm@strides.com, www.strides.com

May 15, 2022

**Kind Attn: Payal Banerjee
The Press Trust of India
Delhi Bureau**

Dear Madam,

We refer to the report /coverage put out by your organization on **“Unable to sell Sputnik Light stock, Stelis Biopharma requests PM Modi for procurement of jabs”** which was published by leading media houses online. We wish to submit the background of the letter we wrote, which formed the basis for the above coverage.

1. The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), and Stelis Biopharma Limited(Stelis or Company), on March 19, 2021, entered into a manufacturing and supply agreement to produce up to 200 million doses of the Russian Sputnik Covid-19 vaccine.
2. Stelis is an emerging Contract Development and Manufacturing Organization(CDMO) dedicated to the biologics and vaccine space.
3. Over the last five years, the company has made significant investments to become a leading global CDMO player in the biologics and vaccine space. We recently expanded by building a new greenfield multi-modal facility in Bangalore, India, for vaccines, biologics, new modalities and also to accommodate the Sputnik vaccine's opportunity.
4. The vaccine block of the above facility was constructed in a record period and was successfully inspected¹ to produce vaccines by the Central Drugs Standard Control Organization (CDSCO).
5. Additionally, Stelis successfully completed the technology transfer of the Sputnik Light vaccine from the Russian Gamaleya National Center of Epidemiology and Microbiology (Gamaleya), the IP holder of the vaccine.
6. In November 2021, Stelis received its first order of 50 million doses of the Sputnik light vaccine to be exported to Russia. We also received the Government of India’s No Objection Certificate (NOC) to export. Against the 50 million doses to be exported, Stelis has produced approximately 23 million doses in different batches.
7. Considering the geopolitical challenges regarding exports to Russia, while the management is discussing with our partners to initiate exports to Russia, we have also reached out to the Prime Minister’s Office (PMO) for their intervention and to evaluate opportunities to sell our inventory in India.
8. More than 90% of the inventory produced by Stelis has a remaining shelf life of one year, and Stelis is confident of finding resolutions to selling the vaccine.

We request you to disseminate the above facts through a corrigendum/follow-up story to keep the stakeholders abreast with the complete facts.

For Stelis Biopharma Limited


Kannan PR
Executive Director

¹ https://strides.com/pdf/pressrelease/2021/strides_se_intimation_20211221.pdf



About Stelis Biopharma Limited (Stelis)

Stelis is an emerging global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a complete and integrated end-to-end offering. It is equipped with world-class Process Development (PD) and manufacturing infrastructure for both drug substances (mammalian and microbial-based therapeutic proteins, viral vectors, and other emerging modalities) and drug products (lyophilized vials, liquid vials, pre-filled syringes, cartridges, and devices). Stelis offers the complete spectrum of services, from cell line tech transfer to clinical and commercial manufacturing, with in-house capability to convert drug substances to stable formulations and fill and finish in all formats. Stelis has three state-of-the-art facilities, with ~9,00,000 square feet of PD and manufacturing space. All its facilities are highly automated to increase accuracy, efficiency, and speed at every process stage.

More details on www.stelis.com

Stelis Biopharma Limited

CORP OFF: #293, Jigani Link Road, Bommasandra,
Anekal Taluk, Bangalore – 560 105, India
Tel: +91 80 6784 0444
E: info@stelis.com | W: www.stelis.com
CIN: U74140KA2007PLC043095